Anti CD19 Gene Therapy for B-cell Lymphoma

This study tests a gene therapy approach to treat relapsed or treatment-resistant B-cell lymphoma. It involves modifying a patient's own immune cells (T-cells) to target CD19 — a protein found on cancerous B-cells — turning the immune system into a precision weapon against the cancer. **You may be eligible if...** - You are 18 or older - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, or another aggressive B-cell lymphoma - Your cancer has relapsed or did not respond after at least two lines of standard treatment - Your cancer cells express the CD19 protein **You may NOT be eligible if...** - You have not received at least second-line standard treatment - Your cancer does not express CD19 - You have serious health conditions that make this experimental therapy too risky Talk to your doctor to see if this trial is right for you.